Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

Redas Trepiakas; Annika Berntsen; Sine Reker Hadrup; Jon Bjørn; Poul F. Geertsen; Per Thor Straten; Mads Hald Andersen; Anders Elm Pedersen; Amir Soleimani; Torben Lorentzen; Julia S. Johansen; Inge Marie Svane

doi:10.3109/14653241003774045

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

Redas Trepiakas, Annika Berntsen, Sine Reker Hadrup, Jon Bjørn, Poul F. Geertsen, Per Thor Straten, Mads Hald Andersen, Anders Elm Pedersen, Amir Soleimani, Torben Lorentzen, Julia S. Johansen, Inge Marie Svane

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.

Original language	English
Journal	Cytotherapy
Volume	12
Issue number	6
Pages (from-to)	721-734
Number of pages	14
ISSN	1465-3249
DOIs	https://doi.org/10.3109/14653241003774045
Publication status	Published - 2010
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/14653241003774045

OpenUrl availability

Full text

Cite this

Trepiakas, R., Berntsen, A., Hadrup, S. R., Bjørn, J., Geertsen, P. F., Straten, P. T., Andersen, M. H., Pedersen, A. E., Soleimani, A., Lorentzen, T., Johansen, J. S., & Svane, I. M. (2010). Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy, 12(6), 721-734. https://doi.org/10.3109/14653241003774045

@article{b994a54e801c42c4b1e591cfcf6b5f51,

title = "Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial",

abstract = "Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.",

author = "Redas Trepiakas and Annika Berntsen and Hadrup, {Sine Reker} and Jon Bj{\o}rn and Geertsen, {Poul F.} and Straten, {Per Thor} and Andersen, {Mads Hald} and Pedersen, {Anders Elm} and Amir Soleimani and Torben Lorentzen and Johansen, {Julia S.} and Svane, {Inge Marie}",

year = "2010",

doi = "10.3109/14653241003774045",

language = "English",

volume = "12",

pages = "721--734",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Elsevier",

number = "6",

}

Trepiakas, R, Berntsen, A, Hadrup, SR, Bjørn, J, Geertsen, PF, Straten, PT, Andersen, MH, Pedersen, AE, Soleimani, A, Lorentzen, T, Johansen, JS & Svane, IM 2010, 'Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial', Cytotherapy, vol. 12, no. 6, pp. 721-734. https://doi.org/10.3109/14653241003774045

TY - JOUR

T1 - Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

AU - Trepiakas, Redas

AU - Berntsen, Annika

AU - Hadrup, Sine Reker

AU - Bjørn, Jon

AU - Geertsen, Poul F.

AU - Straten, Per Thor

AU - Andersen, Mads Hald

AU - Pedersen, Anders Elm

AU - Soleimani, Amir

AU - Lorentzen, Torben

AU - Johansen, Julia S.

AU - Svane, Inge Marie

PY - 2010

Y1 - 2010

N2 - Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.

AB - Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.

U2 - 10.3109/14653241003774045

DO - 10.3109/14653241003774045

M3 - Journal article

C2 - 20429791

SN - 1465-3249

VL - 12

SP - 721

EP - 734

JO - Cytotherapy

JF - Cytotherapy

IS - 6

ER -

Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

Abstract

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this